101,352 results match your criteria Multiple Sclerosis


Home treatment against fatigue in multiple sclerosis by a personalized, bilateral whole-body somatosensory cortex stimulation.

Mult Scler Relat Disord 2022 Apr 17;63:103813. Epub 2022 Apr 17.

Neuroscience and Imaging, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy.

Background: Fatigue in multiple sclerosis (MS) is a highly invalidating symptom with no pharmacological efficacious therapies, which furthermore present frequent severe side effects. In two previous randomized controlled trials we observed the efficacy of a personalized neuromodulation treatment consisting of a personalized transcranial Direct Current Stimulation (tDCS) for 15 min per day for 5 days (Faremus).

Methods: By this medical-device phase II study, we aimed at assessing the feasibility, acceptance, safety and efficacy of Faremus treatment when applied at patients' home. Read More

View Article and Full-Text PDF

Defining milestones for the study of remyelination using the cuprizone mouse model: How early is early?

Mult Scler Relat Disord 2022 May 15;63:103886. Epub 2022 May 15.

Faculty of Medicine, Institute of Pharmacology and Experimental Therapeutics & Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Celas, Coimbra 3000-548, Portugal; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal; Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.

Background: Cuprizone (CPZ) is a copper chelator used to produce a reversible oligodendrocytopathy in animals, which has some similarities to the pathology found in human multiple sclerosis (MS). This model is attractive to study remyelination.

Aims: To demonstrate that a two-week period after cessation of CPZ exposure is sufficient to establish changes compatible with remyelination, without accompanying behavior or brain magnetic resonance imaging (MRI) disturbances. Read More

View Article and Full-Text PDF

Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.

Mult Scler Relat Disord 2022 May 7;63:103857. Epub 2022 May 7.

Department of Social Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Background: One of the most challenging issues in patients with multiple sclerosis is the discontinuation of Disease-Modifying Treatments (DMTs) and subsequent complications.

Objective: We aimed to investigate the extent of adherence to DMTs in naïve multiple sclerosis patients, outcomes of non-adherence to treatments, and the risk factors that lead to drug discontinuation.

Materials And Methods: In this prospective cohort study, 288 naïve cases of Relapsing-Remitting Multiple Sclerosis (RRMS) with the age of 18 years and older were included. Read More

View Article and Full-Text PDF

Feedback from neurology residents and neuroimmunology fellows about the practical training in multiple sclerosis.

Mult Scler Relat Disord 2022 Apr 25;63:103821. Epub 2022 Apr 25.

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Electronic address:

Objective: To obtain feedback from Neurology residents and Neuroimmunology fellows about the practical training in multiple sclerosis (MS).

Methods: A survey was developed and administered electronically to Neurology residents or Neuroimmunology fellows that received training in eight large MS outpatient clinics in Brazil, from 2018 to 2021. We evaluated their beliefs on: (1) the optimal number of MS patients evaluated in a 4-hour outpatient clinic session, (2) the quality of dedicated MS medical records, (3) the training of the neurological exam in MS patients, (4) the teaching discussion with the attending neuroimmunologist and (5) the prescription of MS disease-modifying drugs (DMDs). Read More

View Article and Full-Text PDF

ONSET OF MULTIPLE SCLEROSIS IS PREVENTABLE - TIME TO ACT NOW!

Mult Scler Relat Disord 2022 May 11;62:103875. Epub 2022 May 11.

Department of Pediatrics (Neurology), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto, Toronto,Ontario, Canada.

View Article and Full-Text PDF

Cuprizone-mediated demyelination reversibly degrades voiding behavior in mice while sparing brainstem reflex.

J Neurosci Res 2022 May 20. Epub 2022 May 20.

Department of Neuroscience, University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Multiple sclerosis (MS) is a chronic, progressively debilitating demyelinating disease of the central nervous system (CNS). Nearly 80% of MS patients experience lower urinary tract dysfunction early in their diagnosis. This significantly affects the quality of life, and in latter stages of disease is a leading cause of hospitalization. Read More

View Article and Full-Text PDF

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.

Eur J Health Econ 2022 May 20. Epub 2022 May 20.

Faculty of Health Sciences, Universidad Castilla-La Mancha, 45600, Talavera de la Reina, Toledo, Spain.

Background: Multiple sclerosis imposes a heavy burden on the person who suffers from it and on the relatives, due to the caregiving load involved. The objective was to analyse whether the inclusion of social costs in economic evaluations of multiple sclerosis-related interventions changed results and/or conclusions.

Methods: A systematic review was launched using Medline and the Cost-Effectiveness Analysis Registry of Tufts University (2000-2019). Read More

View Article and Full-Text PDF

School performance and psychiatric comorbidity in juvenile absence epilepsy and juvenile myoclonic epilepsy: a Danish population-based cohort study.

J Neurol 2022 May 20. Epub 2022 May 20.

Department of Clinical Neurophysiology, Copenhagen University Hospital, Copenhagen, Denmark.

Background: We aimed to determine school performance and psychiatric comorbidity in juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures (GTCS) alone.

Methods: All children (< 18 years) fulfilled International League Against Epilepsy criteria after review of their medical records. Control groups were the pediatric background population or children with non-neurological chronic disease. Read More

View Article and Full-Text PDF

Multiple sclerosis in patients with hereditary spastic paraplegia: a case report and systematic review.

Neurol Sci 2022 May 21. Epub 2022 May 21.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, 40139, Bologna, Italy.

Introduction: An increasing number of cases of comorbid hereditary spastic paraplegia (HSP) and multiple sclerosis (MS) have been described. We report a patient with the SPG3A form of HSP and features of relapsing-remitting MS (RRMS). We took this opportunity to review the current literature of co-occurring MS and HSP. Read More

View Article and Full-Text PDF

Rummeliibacillus suwonensis: First Time Isolation from Human Feces by Culturomics.

Curr Microbiol 2022 May 20;79(7):197. Epub 2022 May 20.

Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Gut microbiota is a complex ecosystem composed by trillions of microorganisms that are crucial for human health or disease status. Currently, there are two methodological options to explore its complexity: metagenomics and culturomics. Culturomics is an approach that uses multiple culture conditions (days of incubation, enrichment factors and growth temperature) and MALDI-TOF mass spectrometry for the identification of bacterial species and sequencing when this method fails. Read More

View Article and Full-Text PDF

Rare antibody-mediated and seronegative autoimmune encephalitis: An update.

Autoimmun Rev 2022 May 17:103118. Epub 2022 May 17.

Department of Neuroscience, Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, Australia; Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia; Department of Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Electronic address:

Paralleling advances with respect to more common antibody-mediated encephalitides, such as anti-N-methyl-D-aspartate receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) Ab-mediated encephalitis, the discovery and characterisation of novel antibody-mediated encephalitides accelerated over the past decade, adding further depth etiologically to the spectrum of antibody-mediated encephalitis. Herein, we review the major mechanistic, clinical features and management considerations with respect to anti-γ-aminobutyric acid B (GABA)-, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropinoic receptor- (AMPAR), anti-GABA-, anti-dipeptidyl-peptidase-like protein-6 (DPPX) Ab-mediated encephalitides, delineate rarer subtypes and summarise findings to date regarding seronegative autoimmune encephalitis. Read More

View Article and Full-Text PDF

Implications of lower extremity muscle power and force for walking and fatigability in multiple sclerosis - An exploratory pilot-study.

Clin Biomech (Bristol, Avon) 2022 May 14;96:105668. Epub 2022 May 14.

Faculty of Physical Education, University of Brasília, Brasília, Brazil; Faculty of Ceilândia, University of Brasília, Brasília, Brazil.

Background: Limitations in physical function are common in Multiple Sclerosis (MS), yet it is neither clear how muscle power implicates physical function and walking-fatigability. This pilot-study aims to investigate (1) deficits in muscle power/force alongside walking in persons with MS; (2) associations between muscle power/force and physical functions and (3) the impact of prolonged walking in muscle power/force.

Methods: 30 relapse-remitting persons with MS and 28 healthy controls performed chair rise and plantar flexion on a force platform before and after 12-minutes of intermittent walking to measure lower extremity muscle power/force. Read More

View Article and Full-Text PDF

The analysis of dynamic gene expression patterns in peripheral blood of multiple sclerosis patients indicates possible diagnostic and prognostic biomarkers.

Mol Immunol 2022 May 17;147:147-156. Epub 2022 May 17.

School of Life Sciences, Forman Christian College (A Chartered University), Lahore 54600, Pakistan. Electronic address:

Introduction: Among numerous invasive procedures for the research of biomarkers, blood-based indicators are regarded as marginally non-invasive procedures in the diagnosis and prognosis of demyelinating disorders, including multiple sclerosis (MS). In this study, we looked into the blood-derived gene expression profiles of patients with multiple sclerosis to investigate their clinical traits and linked them with dysregulated gene expressions to establish diagnostic and prognostic indicators.

Methods: We included 51 patients with relapsing-remitting MS (RRMS, n = 31), clinically isolated syndrome (CIS, n = 12), primary progressive MS (PPMS, n = 8) and a control group (n = 51). Read More

View Article and Full-Text PDF

Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups.

Mult Scler Relat Disord 2022 May 4;63:103845. Epub 2022 May 4.

Neurology Service, Department of Neurosciences, Hospital de Santo António/Centro Hospitalar Universitário do Porto; Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas de Abel Salazar da Universidade do Porto.

Introduction: Several neuroimmunological disorders have distinct phenotypes according to the age of onset, as in multiple sclerosis or myasthenia gravis. It is also described that late onset NMOSD (LONMOSD) has a different phenotype.

Objective: To describe the clinical/demographic characteristics of the LONMOSD and distinguish them from those with early onset (EONMOSD). Read More

View Article and Full-Text PDF

HLA-genotyping by next-generation-sequencing reveals shared and unique HLA alleles in two patients with coexisting neuromyelitis optica spectrum disorder and thymectomized myasthenia gravis: Immunological implications for mutual aetiopathogenesis?

Mult Scler Relat Disord 2022 May 8;63:103858. Epub 2022 May 8.

Multiple Sclerosis and Demyelinating Diseases Unit, A' Department of Neurology, Medical School, National and Kapodistrian University of Athens, Aeginition University Hospital, Vas. Sophias, 74, Athens 115 28, Greece; Research Immunogenetics Laboratory, A' Department of Neurology, Medical School, National and Kapodistrian University of Athens, Aeginition University Hospital, Athens, Greece. Electronic address:

The exact immunopathogenesis, genetic mechanisms and triggering factors underlying myasthenia gravis (MG) and neuromyelitis optica (NMO) remain unknown and the coexistence may underline an aetiopathogenetic link be- tween these two diseases. We report the cases of two thymectomized patients with acetylcholine receptor (AChR) antibody (Ab)-positive MG who eventually developed AQP4-NMO. Next-Generation Sequencing (NGS) analysis showed that patient-1 had two HLA alleles previously associated with MG, mainly HLA-A*01:01:01 and HLA-DRB1*03:01, present in a haplotype in Caucasian MG patients (HLA-A1-B8-DR3-DQ2). Read More

View Article and Full-Text PDF

Validity and reliability of the 3-meter backward walk test in patients with multiple sclerosis.

Mult Scler Relat Disord 2022 May 4;63:103842. Epub 2022 May 4.

Department of Physiotherapy and Rehabilitation, SANKO University, Faculty of Health Science, Gaziantep, Turkey.

Background: The 3-meter backward walk test (3MBWT) evaluates neuromuscular control, proprioception, protective reflexes, fall risk, and balance. This study aimed to examine the reliability, validity, and minimal detectable change (MDC) of the 3MBWT in patients with Multiple Sclerosis (pwMS).

Methods: 40 pwMS (8 male, 32 female) were included in the study. Read More

View Article and Full-Text PDF

Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.

Curr Protoc 2022 May;2(5):e437

Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.

Autologous hematopoietic stem cell transplantation (aHSCT) is increasingly used to treat patients with highly active multiple sclerosis (MS) refractory to disease-modifying therapy. Briefly, cyclophosphamide and filgrastim are used to mobilize autologous hematopoietic stem cells (HSC) into the circulation. HSC are harvested by leukapheresis, purified using a CD34 immunomagnetic selection process, and cryopreserved. Read More

View Article and Full-Text PDF

NURR1-deficient mice have age- and sex-specific behavioral phenotypes.

J Neurosci Res 2022 May 20. Epub 2022 May 20.

Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy.

The transcription factor NURR1 is essential to the generation and maintenance of midbrain dopaminergic (mDA) neurons and its deregulation is involved in the development of dopamine (DA)-associated brain disorders, such as Parkinson's disease (PD). The old male NURR1 heterozygous knockout (NURR1-KO) mouse has been proposed as a model of PD due to its altered motor performance that was, however, not confirmed in a subsequent study. Based on these controversial results, we explored the effects of the NURR1 deficiency on locomotor activity, motor coordination, brain and plasma DA levels, blood pressure and heart rate of old mice, also focusing on the potential effect of sex. Read More

View Article and Full-Text PDF

Myeloid cell-specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation.

EMBO Rep 2022 May 20:e54499. Epub 2022 May 20.

Applied Immunology and Immunotherapy, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.

Targeting myeloid cells, especially microglia, for the treatment of neuroinflammatory diseases such as multiple sclerosis (MS), is underappreciated. Our in silico drug screening reveals topoisomerase 1 (TOP1) inhibitors as promising drug candidates for microglial modulation. We show that TOP1 is highly expressed in neuroinflammatory conditions, and TOP1 inhibition using camptothecin (CPT) and its FDA-approved analog topotecan (TPT) reduces inflammatory responses in microglia/macrophages and ameliorates neuroinflammation in vivo. Read More

View Article and Full-Text PDF

The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia.

Cureus 2022 Apr 16;14(4):e24181. Epub 2022 Apr 16.

Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, SAU.

Introduction Multiple sclerosis (MS) is an autoimmune disease that can be disabling to patients. Smoking has been proposed to be a risk factor for MS and to increase the risk of progression of the disease and its severity. However, it is still not clear how smoking affects people with MS (PwMS) regarding disease phenotype, symptoms, relapses, course, and disability. Read More

View Article and Full-Text PDF

A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: analysis in relation to the newly-described 'Spasticity-Plus syndrome'.

Eur J Neurol 2022 May 19. Epub 2022 May 19.

Global Medical Affairs, Almirall S.A., Barcelona, Spain.

Background And Purpose: Nabiximols is a therapeutic option for patients with multiple sclerosis (MS) spasticity whose symptoms are poorly controlled by conventional oral first-line medications. This study aimed to assess the relationship between changes in spasticity severity (measured on the 0-10 numerical rating scale [NRS]) and the presence of associated symptoms in patients treated with nabiximols; and to investigate the presence of the newly-described 'Spasticity-Plus syndrome'.

Methods: We analyzed real-world data from the Italian Medicines Agency e-Registry for 1138 patients with MS spasticity who began treatment with nabiximols. Read More

View Article and Full-Text PDF

Targeting Epstein-Barr virus to treat MS.

Med (N Y) 2022 Mar;3(3):159-161

Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115 USA. Electronic address:

Epstein-Barr virus (EBV) is a putative trigger for multiple sclerosis (MS). Bjornevik et al. utilized longitudinal analysis of 10 million adults to strongly link MS to EBV infection and Lanz et al. Read More

View Article and Full-Text PDF

Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

CNS Drugs 2022 May 19. Epub 2022 May 19.

Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

The development of antidrug antibodies (ADAs) is a major problem in several recombinant protein therapies used in the treatment of multiple sclerosis (MS). The etiology of ADAs is multifaceted. The predisposition for a breakdown of immune tolerance is probably genetically determined, and many factors may contribute to the immunogenicity, including structural properties, formation of aggregates, and presence of contaminants and impurities from the industrial manufacturing process. Read More

View Article and Full-Text PDF

Differential Regulation of Mouse Hippocampal Gene Expression Sex Differences by Chromosomal Content and Gonadal Sex.

Mol Neurobiol 2022 May 20. Epub 2022 May 20.

Genes & Human Disease Program, Oklahoma Medical Research Foundation, 825 NE 13thStreet, Oklahoma City, OK, 73104, USA.

Common neurological disorders, like Alzheimer's disease (AD), multiple sclerosis (MS), and autism, display profound sex differences in prevalence and clinical presentation. However, sex differences in the brain with health and disease are often overlooked in experimental models. Sex effects originate, directly or indirectly, from hormonal or sex chromosomal mechanisms. Read More

View Article and Full-Text PDF

The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis.

Mol Neurobiol 2022 May 19. Epub 2022 May 19.

Department of Experimental and Clinical Pharmacology, Center for Preclinical Research and Technology CEPT, Medical University of Warsaw, Banacha 1B str., 02-097, Warsaw, Poland.

Multiple sclerosis (MS) is a central nervous system chronic neuroinflammatory disease followed by neurodegeneration. The diagnosis is based on clinical presentation, cerebrospinal fluid testing and magnetic resonance imagining. There is still a lack of a diagnostic blood-based biomarker for MS. Read More

View Article and Full-Text PDF

Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab.

Acta Neurol Belg 2022 May 19. Epub 2022 May 19.

Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium.

View Article and Full-Text PDF

[Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Who Have Already Visited Some Medical Institutions: Diagnosis, Treatment and Research].

Authors:
Wakiro Sato

Brain Nerve 2022 May;74(5):652-659

Department of Immunology, Multiple Sclerosis Center, National Center of Neurology and Psychiatry, National Institute of Neuroscience.

Myalgic encephalitis/chronic fatigue syndrome (ME/CFS) is an acquired intractable disease characterized by profound fatigue, post-exertional malaise, sleep disturbance, cognitive impairment, and orthostatic intolerance, among other features. The onset often follows an infectious episode. Importantly, the various types of autonomic dysfunctions, pain, and intolerance to various stimuli in ME/CFS patients are intrinsically different from the "fatigue" of healthy individuals. Read More

View Article and Full-Text PDF

[Disability Progression in SPMS Despite Therapeutic Intervention: Current Status and Perspectives of Treatment with Disease-Modifying Drugs].

Authors:
Takashi Ohashi

Brain Nerve 2022 May;74(5):505-509

Division of Neurology, Department of Internal Medicine, Tokyo Women's Medical University Yachiyo Medical Center.

Currently, siponimod is the only disease-modifying drugs (DMDs) with proven efficacy and safety in clinical trials for secondary progressive multiple sclerosis (SPMS). However, the efficacy of siponimod in preventing disability progression is insufficient and it has not yet been able to deter disability progression. Therefore, it is considered necessary to use DMDs with a high relapse-preventive effect at a relatively early stage of SPMS, while disease activity remains evident. Read More

View Article and Full-Text PDF

[Disability Progression in SPMS Despite Therapeutic Intervention: Refractory SPMS].

Authors:
Hirofumi Ochi

Brain Nerve 2022 May;74(5):496-504

Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine.

New disease-modifying drugs (DMDs), such as ocrelizumab and Siponimod, have been proven to be efficacious for treating progressive multiple sclerosis (MS) and have marked a new era in the treatment of this disease. However, these drugs work on the inflammatory component of the disease, and their potential effect on the neurodegenerative aspect of MS is likely to be modest. Therefore, the treatment of progressive MS continues to be challenging in routine clinical practice. Read More

View Article and Full-Text PDF